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ABSTRACT 
Insulin-degrading enzyme (IDE) is a 110 kDa chambered zinc metalloendopeptidase that degrades 
insulin, amyloid beta, and other intermediate-sized aggregation prone peptides that adopt β-structures. 
Structural studies of IDE in complex with multiple physiological substrates have suggested a role for 
hydrophobic and aromatic residues of the IDE active site in substrate binding and catalysis. Here, we examine 
functional requirements for conserved hydrophobic and aromatic IDE active site residues that are positioned 
within 4.5 Angstroms of IDE bound insulin B chain and amyloid beta peptides in the reported crystal structures 
for the respective enzyme-substrate complexes. Charge, size, hydrophobicity, aromaticity, and other 
functional group requirements for substrate binding IDE active site residues were examined through 
mutational analysis of the recombinant human enzyme and enzyme kinetic studies conducted using native 
and fluorogenic derivatives of human insulin and amyloid beta peptides. A functional requirement for IDE 
active site residues F115, A140, F141, Y150, W199, F202, F820, and Y831 was established, and specific 
contributions of residue charge, size and hydrophobicity in substrate binding, specificity, and proteolysis were 
demonstrated. IDE mutant alleles that exhibited enhanced or diminished proteolytic activity towards insulin or 
amyloid beta peptides and derivative substrates were identified. 
 
 
INTRODUCTION  
Human insulin-degrading enzyme (IDE; EC 3.4.24.56, GenBank reference sequence BC096336) is a 110 kDa 
chambered zinc metalloendopeptidase of the M16A subfamily.  The enzyme is notable for its role in the 
proteolysis of several physiologically significant peptides that adopt β-structures, including insulin (1, 2), 
glucagon (3), amylin (4) and amyloid beta (Aβ) peptides (5). 
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Multiple studies point to roles for IDE in metabolic signaling and disease. Consistent with a role for IDE 
within the insulin signaling pathway, human IDE polymorphisms have been associated with type 2 diabetes (6, 
7), and in IDE deficient mouse models, loss of IDE corresponds with elevated serum insulin and glucose levels, 
and intolerance to glucose challenge after fasting (8, 9). Moreover, in accordance with the amyloid hypothesis, 
which asserts that variations in neuronal Aβ production and catabolism contribute to the development of 
Alzheimer’s disease (10, 11, 12), IDE is thought to play a neuroprotective role in the clearance of free Aβ 
peptides (8, 13, 14, 15). Proteolytic clearance of Aβ peptides by IDE is hypothesized to limit peptide 
accumulation, plaque formation and neurotoxicity (16, 17, 18, 19). Consistent with this hypothesis, transgenic 
mice that overexpress amyloid precursor protein exhibit cognitive deficits, whereas neuronal levels of Aβ and 
premature death rates are significantly reduced in transgenic mice where IDE is overexpressed in parallel (20), 
and primary neurons cultured from IDE knockout mice show >90% reduction in the rate of Aβ degradation (8). 
IDE is a member of the M16A subfamily of zinc metalloendopeptidases. M16A peptidases are broadly 
conserved, with homologs expressed throughout the prokaryotic and eukaryotic kingdoms (21, 22). M16A 
enzymes hydrolyze intermediate-sized (<10 kDa) peptides with propensity to adopt β-structures at multiple 
cleavage sites, breaking substrates into smaller fragments or component amino acids. Molecular determinants 
of substrate recognition by IDE have been examined previously (5, 17, 19, 23, 24). A distinguishing feature that 
is shared among IDE substrates is a common propensity to form β-structure interactions with the β6 strand of 
the IDE active site (23, 24). No absolute primary sequence requirement is recognized among IDE substrates 
(25). However, studies of rat IDE using synthetic fluorogenic peptides revealed preferential cleavage specificity 
on the amino side of bulky hydrophobic and basic residues and support the assignment of an extended 
substrate binding site (26, 27). Substrates of IDE and other M16A enzymes must be small enough to fit within 
the substrate binding chamber to facilitate proteolysis, and peptides with pronounced electropositive 
character at their carboxy-termini may be poor IDE substrates due to repulsive electrostatic interactions with 
the electropositive C-terminal face of the substrate binding chamber (23).  In addition, larger IDE substrates 
also interact with IDE at one or more exosites, located as much as 30 Å or more from the catalytic center (23, 
28, 29). 
Structural data is available for IDE alone (30), as well as in complex with insulin, Aβ, amylin and glucagon 
(23, 31).  Like other enzymes of the M16A subfamily, IDE adopts a structure analogous to that of a clamshell, 
with large (~50 kDa) N- and C-terminal domains positioned about a central cavity.  The opening and closing of 
the N- and C- terminal domains is required to facilitate substrate access to the enzyme active site and may 
represent a rate limiting step within the IDE catalytic mechanism (23). The mode of substrate binding to the 
open IDE conformer has been recently elucidated by structural studies conducted using electron microscopy, 
suggesting that amyloidogenic peptides stabilize the disordered catalytic cleft, facilitating selective 
degradation through substrate-assisted catalysis (31). In the reported substrate bound closed crystal 
structures, IDE substrates are enclosed within a large (16,000 Å3) central binding chamber, or “crypt”. Herein, 
the catalytic Zn2+ ion is coordinated by residues of the invariant HXXEH (inverzincin) motif that is conserved 
among all M16 family proteases (21, 32, 33).   
The IDE inverzincin motif includes several enzymatic residues that are critical for Zn2+ binding and 
catalysis (21, 32, 33) while the catalytic Zn2+ ion itself is positioned near an extended β-sheet that forms 
multiple contacts with substrates adopting β-strand conformations in the reported substrate bound IDE crystal 
structures (23).  Within and around this substrate interfacing β-sheet, IDE contains several conserved 
hydrophobic and aromatic residues that are positioned in close proximity to hydrophobic regions of bound 
substrates with high β-propensity (23, 24). Substrate specificity of IDE and other M16A homologs has thus 
been proposed to depend on the character of hydrophobic and aromatic active site residues that are proximal 
to the catalytic zinc ion within the enzyme’s central catalytic chamber (23). Yet, few experimental efforts have 
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sought to directly investigate specificity determinants of the IDE active site, and studies of IDE active site 
substrate specificity determinants using native IDE substrates or their derivatives are particularly lacking.   
This study examines the molecular basis of substrate specificity of human IDE through mutational 
analysis of conserved hydrophobic and aromatic IDE active site residues positioned within 4.5 Å of insulin B 
chain and Aβ 1-40 in the substrate bound IDE crystal structures PDB ID 2G54 and PDB ID 2G47 (23). Purified 
bacterially expressed human IDE, recombinant insulin and Aβ peptides, and quenched fluorogenic (FRET) 
peptide derivatives thereof were used to probe the functional contributions of IDE active site residues in 
substrate recognition and proteolysis.  We observe that conserved hydrophobic and aromatic residues of the 
IDE active site are critical for substrate binding and enzyme activity and report the identification of IDE mutant 
alleles that exhibit hyperactive proteolytic activity towards insulin or Aβ derivative FRET substrates, as well as 
IDE mutants that exhibit increased selectivity for proteolysis of insulin or Aβ peptides.  
 
RESULTS 
Identification of conserved hydrophobic and aromatic substrate interfacing residues of the IDE active site 
The requirement for conserved hydrophobic and aromatic IDE active site residues within 4.5 Å of insulin 
B chain or Aβ 1-40 peptides in crystal structures PDB ID 2G54 and PDB ID 2G47 (23) was evaluated through 
kinetic study of recombinant human IDE mutants. Insulin, Aβ 1-40 and derivative quenched fluorogenic 
peptides that were developed for use in this study were applied to characterize the proteolytic activity of 
purified IDE in vitro. Conserved hydrophobic and aromatic IDE active site residues that were characterized by 
mutational and kinetic study are depicted in Figure 1.  
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Figure 1. Conserved hydrophobic and aromatic substrate interfacing residues of the IDE active site.  A. Structural model of IDE (grey ribbons) in 
complex with insulin B chain (main chain carbon atoms are represented by cyan sticks; positions of oxygen and nitrogen atoms are indicated in red 
and blue, respectively); this image has been adapted from structural coordinates reported in PDB ID 2G54 (23). Conserved hydrophobic and 
aromatic residues of the IDE active site that were subject to mutational analysis in this study are indicated (yellow sticks). In the perspective shown, 
exterior residues of IDE that obscure bound substrate have been rendered transparent to reveal the enzyme active site. B. Space-filling 
representation of IDE in complex with insulin B chain (23). Conserved hydrophobic and aromatic residues of the IDE active are represented as solid 
yellow spheres, with the region of defined electron density for insulin B chain shown in cyan (carbon atoms), blue (nitrogen), red (oxygen) and 
yellow (sulfur) punctate surfaces. The catalytic Zn2+ ion, partially occluded, is shown as a purple sphere. C. Space-filling representation of IDE in 
complex with Aβ 1-40 peptide (PDB ID 2G47). Regions of defined electron density for Aβ 1-40 carbon atoms are represented as green punctate 
surfaces.  
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To examine specific functional group requirements for IDE active site residues, targeted mutagenic 
substitutions introduced amino acid residues with varying hydrophobicity, charge, size, and aromaticity in 
place of conserved hydrophobic and aromatic residues of the IDE active site. Targeted substitutions were 
introduced through inverse PCR amplification of the wild-type IDE expression construct (i.e., IDE(M42-L1019)-
6xHis; hereafter referred to as “WT IDE”) using mutagenic oligonucleotide primers (Table S1). The proximity of 
IDE active site residues targeted by mutational analysis to regions of substrate electron density in the reported 
insulin B chain and Aβ 1-40 bound IDE crystal structures (23) is described in Table S2. Hydrogen atoms are 
omitted from structural representations and were not considered in calculations of residue proximity. All 
mutants characterized in this study were readily expressed and purified by immobilized metal affinity 
chromatography and were isolated as proteins of the expected molecular mass (Figure S1). A multiple 
sequence alignment of eukaryotic and prokaryotic IDE homologs, indicating the positions of active site 
residues that were targeted for mutagenesis within this study is presented in Figure S2.  
Application of insulin B chain and Aβ derivative FRET substrates for real-time kinetic analysis of IDE 
proteolytic activity is presented in Figure 2. Addition of WT IDE but not the catalytically inactive (32) IDE 
E111Q mutant to proteolytic assays conducted using insulin B chain and Aβ derivative FRET substrates 
resulted in increased sample fluorescence over time (Figure 2A and 2B, respectively).  For each substrate, a 
linear correlation between fluorescence intensity and peptide hydrolysis product concentration was 
established and was in turn used to inform kinetic parameters of IDE function (Figures 2C, 2D).  The insulin B 
chain derivative FRET substrate Mca-VEALYLVCGEK(Dnp)-OH was bound by IDE with higher affinity yet was 
hydrolyzed more slowly than the Aβ derivative FRET substrate Mca-QKLVFFAEDVK(Dnp)-OH (Khalf 1.26 ± 0.13 
µM, kcat 11.9 ± 0.7 min
-1 vs. Khalf 3.16 ± 0.69 µM, kcat 34.3 ± 4.4 min
-1
,
 respectively; Figure 2E, 2F and Table 1).  
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Figure 2. Insulin and Aβ derivative fluorogenic substrates for real-time kinetic analysis of IDE activity. A. Reaction progress curve for a 
representative kinetic IDE proteolysis assay conducted using insulin B chain derivative Mca-VEALYLVCGEK(Dnp)-OH FRET substrate and purified 
recombinant IDE.  Sample fluorescence (Relative Fluorescence Units, RFU) is reported as a function of time (s). WT IDE, or the catalytically inactive 
IDE E111Q mutant (28), were added to the reaction mixture to initiate proteolysis, and fluorescence measurements were recorded at 15 s intervals 
(Excitation: 325 ± 25 nm, Emission: 420 ± 25 nm). B. Reaction progress curve from a representative kinetic assay conducted using the Aβ derivative 
fluorogenic substrate Mca-QKLVFFAEDVK(Dnp)-OH. C. Standardization of the fluorogenic assay. Sample fluorescence at endpoint is reported as a 
function of initial substrate concentration for the insulin B chain derivative Mca-VEALYLVCGEK(Dnp)-OH FRET peptide.  D. Standardization of the 
fluorogenic assay, with sample fluorescence at endpoint reported as a function of initial substrate concentration for the Aβ derivative Mca-
QKLVFFAEDVK(Dnp)-OH FRET peptide.   E. Model for kinetic parameters of IDE function. Initial reaction velocity was determined for kinetic assays 
conducted in the presence of varying initial concentrations of Mca-VEALYLVCGEK(Dnp)-OH, as indicated. Kinetic parameters of IDE function 
including Khalf and kcat were derived from this data using the allosteric sigmoidal least squares nonlinear regression functionality of GraphPad PRISM 
v. 7.0. Average values from n=6 experimental replicates ± standard error of the mean are shown. F. Model for kinetic parameters of IDE function at 
varying initial concentrations of Mca-QKLVFFAEDVK(Dnp)-OH. 
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TABLE 1 
Kinetic parameters of IDE proteolysis of insulin and Aβ peptide derivative FRET substrates.  
Enzyme 
isolate 
Mca-VEALYLVCGEK(Dnp)-OH Mca-QKLVFFAEDVK(Dnp)-OH 
Specific activity 
(nmol min-1 mg-1) 
Khalf (μM)       kcat (min
-1) 
Specific activity 
(nmol min-1 mg-1) 
Khalf (μM) kcat (min
-1) 
WT IDE 116 ± 6 1.26 ± 0.14 11.9 ± 0.7 183 ± 12 3.16 ± 0.69 34.3 ± 4.4 
E111Q <1 - - <1  - - 
F115A 14 ± 1 - - 158 ± 6 2.78 ± 1.08 43.5 ± 6.0 
F115W 18 ± 1 - - 129 ± 5 4.26 ± 1.50 43.9 ± 5.2 
F115Y 54 ± 3 0.79 ± 0.58 12.0 ± 4.9 170 ± 8 4.12 ± 1.40 43.3 ± 5.2 
F115N 28 ± 2 - - 21 ± 3 - - 
F115D 4 ± 1 - - 23 ± 2 - - 
F115K <1 - - 4 ± 1 - - 
A140F <1 - - <1 - - 
A140W <1 - - <1 - - 
A140Y <1 - - <1 - - 
A140N <1 - - <1 - - 
A140D <1 - - <1 - - 
A140K <1 - - <1 - - 
F141A 86 ± 2 2.68 ± 0.13 13.0 ± 0.6 85 ± 6 4.11 ± 1.20 19.8 ± 1.8 
F141W 45 ± 1 4.26 ± 0.24 6.1 ± 0.5 221 ± 21 2.61 ± 0.70 37.5 ± 3.7 
F141Y 105 ± 3 2.78 ± 0.06 10.7 ± 0.4 280 ± 17 3.26 ± 0.66 46.8 ± 3.9 
F141N 63 ± 2 3.24 ± 0.08 7.4 ± 0.3 32 ± 2 - - 
F141D 29 ± 2 - - 22 ± 2 - - 
F141K 35 ± 1 - - 14 ±2 - - 
Y150F 96 ± 5 3.01 ± 0.13 13.3 ± 0.7 240 ± 19 4.51 ± 1.57 66.4 ± 9.0 
Y150A 18 ± 4 - - 33 ± 5 - - 
Y150W 55 ± 4 4.28 ± 0.15 8.6 ± 0.5 81 ± 6 5.94 ± 1.74 26.9 ± 2.7 
Y150N 22 ± 1 - - 34 ± 5 - - 
Y150D 27 ± 2 - - 58 ± 2 - - 
Y150K 41 ± 2 3.14 ± 0.08 5.7 ± 0.3 72 ± 5 3.77 ± 0.68 17.9 ± 1.2 
W199F 98 ± 4 2.51 ± 0.16 14.4 ± 0.8 66 ± 4 6.62 ± 2.03 20.3 ± 2.3 
W199A 88 ± 6 3.16 ± 0.13 10.9 ± 0.5 21 ± 1 - - 
W199Y 78 ± 5 2.46 ± 0.10 9.4 ± 0.4 59 ± 4 3.08 ± 0.51 34.2 ± 2.1 
W199N 84 ± 4 2.66 ± 0.11 10.6 ± 0.5 19 ± 1 - - 
W199D 18 ± 1 - - 17 ± 1 - - 
W199K 53 ± 4 1.26 ± 0.13 5.3 ± 0.2  4 ± 2 - - 
F202A 35 ± 3 - - 8 ± 1 - - 
F202W 83 ±4 2.32 ± 0.08 8.9 ± 0.3 167 ± 11 4.85 ± 0.82 48.2 ± 3.3 
F202Y 130 ± 5 2.26 ± 0.10 14.6 ± 0.6 155 ± 5 2.65 ± 0.25 44.1 ± 1.8 
F202N 78 ± 3 3.52 ± 0.05 10.3 ± 0.8 61 ± 5 - - 
F202D 64 ± 5 2.46 ± 0.06 5.8 ± 0.2 119 ± 2 2.46 ± 0.17 31.9 ± 0.9 
F202K 56 ± 2 2.90 ± 0.09 5.8 ± 0.3 13 ± 1 - - 
F820A 7 ± 1 - - 18 ± 3 - - 
F820W 130 ± 8 2.30 ± 0.20 9.6 ± 0.5 196 ±15 2.68 ± 0.51 50.8 ± 3.8 
F820Y 93 ± 7 2.91 ± 0.09 6.5 ± 0.3 71 ± 10 2.71 ± 0.43 17.3 ± 1.0 
F820N 9 ± 1 - - 20 ± 1 - - 
F820D <1 - - 2 ± 1 - - 
F820K 3 ± 2 - - 23 ± 2 - - 
Y831F <1 - - <1 - - 
Y831A <1 - - <1 - - 
Y831W <1 - - <1 - - 
Y831N <1 - - <1 - - 
Y831D <1 - - <1 - - 
Y831K <1 - - <1 - - 
 
Table 1. Kinetic parameters of IDE proteolysis of Mca-VEALYLVCGEK(Dnp)-OH or Mca-QKLVFFAEDVK(Dnp)-OH were determined for WT IDE, the IDE 
catalytic mutant E111Q (28), and other active site mutants described in this study. Kinetic parameters including the specific activity of IDE 
proteolysis at 20 µM initial substrate concentration, substrate concentration corresponding with half-maximal enzymatic activity (Khalf), and 
maximal rate of substrate turnover (kcat) are described. Average values from n=3 experimental replicates are reported ± standard error of the 
mean. For enzyme isolates that retained less than one third the specific activity of WT IDE, Khalf and kcat are not reported (-).   
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Conserved hydrophobic and aromatic residues of the IDE active site are critical to binding and proteolysis of 
insulin and Aβ derivative FRET peptides 
Kinetic studies revealed that conserved hydrophobic and aromatic residues of the IDE active site are 
critical to proteolysis of insulin B chain and Aβ derivative FRET peptides (Table 1). A broad requirement for the 
conserved hydrophobic character of IDE active site residues was evident, as substitutions that introduced 
amino acid residues with hydrophilic or charged character were poorly tolerated. Notably, absolute 
conservation of IDE residues A140 and Y831 was essential to proteolytic activity, as all characterized 
substitutions introduced in place of either residue rendered the enzyme catalytically inactive. The absolute 
requirement for conservation of residue Y831 is in contrast with a prior study (23) that was conducted using 
the quenched fluorogenic peptide Substrate V (Mca-RPPGSFAFK(Dnp)-OH), a derivative of the inflammatory 
mediator bradykinin. Thus, the requirement for hydrophobic and aromatic IDE active site residues appears 
critically dependent on substrate identity.  
A functional requirement for conservation of aromaticity of IDE active site residues was evident, as most 
mutagenic substitutions that introduced hydrophilic and/or charged amino acids in place of residues F115, 
F141, Y150, W199, F202 and F820 retained less than 20% of WT catalytic activity (Figure 3). Catalytically 
inactive IDE mutants were not subjected to further study using FRET peptides. However, mutants that 
retained at least 20% of WT IDE activity were subjected to analysis of kinetic parameters including evaluation 
of binding affinity (Khalf) and turnover number (kcat) towards insulin B chain and Aβ derivative FRET substrates 
(Table1). Among IDE active site mutants that retained substantial catalytic activity, most mutants that 
exhibited a lower rate of peptide substrate turnover also exhibited lower substrate binding affinity, suggesting 
that reduced substrate binding affinity may contribute to reduction in catalytic rate upon mutation of 
hydrophobic and aromatic IDE active site residues.  Intriguingly, a number of hyperactive alleles of IDE, which 
exhibited increased rate of proteolysis of insulin B chain and Aβ derivative FRET peptides were also identified 
(i.e., Y150F, F202Y, and F820W; and F141Y, F141W, Y150F, F202W, F202Y, and F820W mutants, respectively; 
Table 1). Notably, all hyperactive IDE mutants preserved the native aromatic character of the mutagenized 
active site residues. Relative to the catalytic efficiency of WT IDE (10.85 ± 1.39 min-1 µM-1) catalytic efficiency 
towards the Aβ derivative FRET substrate was most significantly increased for the F202Y mutant (16.96 ± 0.68 
min-1 µM-1, while more modest increases were observed for F141W (14.37± 1.42 min-1 µM-1), F141Y (14.36 ± 
1.20 min-1 µM-1) and Y150F mutants (14.72 ± 2.00 min-1 µM-1). Significant increases in catalytic efficiency 
towards the insulin B chain derivative FRET substrate were not observed among the mutants characterized. 
Page 8 of 21
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Functional analysis of the IDE substrate binding interface 
 
 9
 
 
Figure 3. Aromaticity of IDE active site residues is critical for proteolysis. A. Average proteolytic activity of F115, F141, F202, and F820 mutants 
towards the insulin B chain derivative Mca-VEALYLVCGEK(Dnp)-OH peptide, by substitution. Radar graphs depict the relative specific activity of 
mutant enzymes by comparison to WT IDE. B. Average proteolytic activity of F115, F141, F202, and F820 mutants towards the Aβ derivative Mca-
QKLVFFAEDVK(Dnp)-OH peptide, as a percentage of WT IDE activity, by substitution. C. Proteolytic activity of Y150 mutants towards Mca-
VEALYLVCGEK(Dnp)-OH. D. Proteolytic activity of Y150 mutants towards Mca-QKLVFFAEDVK(Dnp)-OH. E. Proteolytic activity of W199 mutants 
towards Mca-VEALYLVCGEK(Dnp)-OH. F. Proteolytic activity of W199 mutants towards Mca-QKLVFFAEDVK(Dnp)-OH. The hydrophobicity of 
mutagenic substitutions decreases clockwise from top (WT) in each panel of the figure.  
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Hydrophobic and aromatic IDE active site residues direct proteolytic specificity towards insulin and Aβ 1-40  
As IDE mutants bearing substitutions in residues A140 and Y831 were unable to cleave insulin and Aβ 
derivative FRET substrates, we examined whether these mutants were similarly inactive towards full-length 
insulin and Aβ 1-40. Proteolysis of full-length recombinant insulin (insulin-FITC) and Aβ 1-40 was examined 
using endpoint proteolysis assays that were evaluated by SDS-PAGE (Figure 4).  By contrast with WT IDE, which 
exhibited proteolytic activity of approximately 2.3 ± 0.1 nmol min-1 mg-1 towards insulin-FITC and 6.9 ± 0.1 
nmol min-1 mg-1 towards Aβ 1-40, the IDE E111Q catalytic mutant and both A140F and Y831F active site 
substitution mutants lacked observable proteolytic activity towards insulin-FITC (Figure 4A, 4C) and also 
towards Aβ 1-40 (Figure 4B, 4D). Thus, conservation of hydrophobicity, aromaticity, and high β-propensity of 
IDE active site residues appears critical to proteolysis of recombinant insulin and Aβ peptides in addition to 
FRET substrates. 
Proteolysis of insulin-FITC and Aβ 1-40 by IDE mutants that exhibited only partial defects in proteolytic 
activity, including several mutants that exhibited apparent preference for cleavage of either insulin B chain or 
Aβ derivative FRET peptides, was similarly evaluated (Figure 5).  IDE mutants that exhibited preferential 
cleavage of either insulin B chain or Aβ derivative FRET substrates were selected on the basis of their apparent 
differential specificity and further characterized using longer peptide substrates. IDE mutants that exhibited 
increased proteolytic selectivity towards insulin-FITC (F141W) and towards Aβ 1-40 (W199K) were identified.  
By comparison with the ease of application of the reported FRET substrates for characterization of IDE 
activity, assays for measurement of insulin-FITC and Aβ 1-40 proteolysis by IDE offered more limited 
throughput and tractability and were accordingly more limited in scope. Not all mutants that exhibited 
increased selectivity towards insulin B chain or Aβ derivative FRET substrates exhibited increased specificity 
towards intact insulin-FITC and Aβ 1-40 (Fig. S9). Thus, IDE specificity determinants are not uniquely limited to 
the conserved hydrophobic and aromatic active site residues characterized in this study.  
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Figure 4. Hydrophobic and aromatic IDE active site residues are essential for proteolysis of insulin and Aβ 1-40.  A. Densitometric analysis of 
insulin-FITC hydrolysis by WT IDE, E111Q, A1140F and Y831F mutants. The amount of insulin-FITC remaining at various intervals within the 
proteolytic time course was determined relative to internal standards for each experiment. Average values from n=2 experimental replicates ± 
standard error of the mean are shown. B. Densitometric analysis of Aβ 1-40 hydrolysis by WT IDE, E111Q, A1140F and Y831F mutants. The amount 
of Aβ 1-40 remaining at various intervals within the proteolytic time course was determined relative to internal standards for each experiment 
(below). C. Representative SDS-PAGE gels from the insulin-FITC proteolytic time course experiment. UV-transilluminated gel images are shown (20 s 
exposure; with fluorescein filter setting of Bio-Rad Gel Doc imaging system). Protein size marker and serially-diluted internal standards of 25 ng, 
12.5 ng, 6.25 and 0 ng insulin-FITC are at positioned left, with proteolytic time course samples positioned towards the right of the gel. While 
present in the proteolytic experiment and where indicated as control, IDE does not exhibit significant fluorescence, and is not visible in the images 
shown. D. Representative Aβ 1-40 proteolytic time course experiment. Coomassie stained SDS-PAGE gel images are shown. Protein size marker and 
serially-diluted internal standards of 1 µg, 0.5 µg, 0.25 µg and 0 µg Aβ 1-40 are shown at left, with proteolytic time course positioned towards the 
right of the gel (bottom panels). IDE inputs are shown as control (top panels). Paired images are derived from the same SDS-PAGE gels. 
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Figure 5. Substrate-selective IDE mutants. Relative rates of Insulin-FITC (black bars) and Aβ 1-40 (white bars) proteolysis by WT IDE and derivative 
mutants. Peptide hydrolysis was determined by densitometric analysis after a 5 minute proteolytic time course experiment relative to amounts of 
peptide hydrolyzed by WT IDE. Average values from n=2 experimental replicates are shown ± standard error of the mean. 
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DISCUSSION 
This study demonstrates a critical role for conserved hydrophobic and aromatic residues of the IDE active 
site in the proteolysis of insulin, Aβ peptides, and fluorogenic peptide derivatives thereof. The functional 
significance of apolar IDE active residues is substrate-dependent and is influenced by both substrate length 
and primary sequence identity.  
Several prior studies have examined the structure of the IDE active site (23) and peptide primary 
sequence determinants of IDE specificity (25, 26, 27). Shen et al. reported structural data for IDE in complex 
with insulin B chain (PDB ID 2G54), Aβ 1-40 (PDB ID 2G47) and other physiological substrates, which identified 
several hydrophobic surfaces of the enzyme in close proximity to bound substrates near ligands of the 
catalytic Zn2+ center (23). IDE substrates form β-sheets with IDE strand β6 (residues S137-S143) adjacent to 
the enzyme active site (23, 24), and form contact interfaces with residues of the α1 (G105-F115) and α5 
(N196-N210) helices, as well as several residues from a conserved but unstructured loop (L823-Y831) of the 
IDE C-terminus.  
IDE exhibits preference for substrates bearing basic or large hydrophobic amino acids near the site of IDE 
proteolytic cleavage but does not exhibit absolute substrate sequence requirements for peptide hydrolysis. 
Studies conducted using short fluorogenic synthetic peptides revealed that substrates which contain arginine, 
phenylalanine, leucine or tyrosine in the P1 or P1’ subsites directly amino or carboxy terminal to the scissile 
peptide bond are cleaved with greatest catalytic efficiency (26, 34). IDE exhibits relative preference for 
efficient cleavage of substrates bearing aromatic or hydrophobic residues in the more distal P2, and to a lesser 
extent P2’ subsites, consistent with the hypothesis that the enzyme contains an extended substrate binding 
site, and that IDE specificity is that is largely dictated substrate 3-dimensional structure (23, 27, 35). In 
addition, larger peptide substrates form binding interactions with IDE exosites located as much as 30 Å distal 
to the enzyme active site (23, 28, 29), in enzymatic regions that are not directly characterized in this study. 
The structural models of Shen et al. (23), and functional models of Song et al. (27), Sefavi et al. (26), and 
others (24, 35) are broadly consistent with the findings from this study, which demonstrate a requirement for 
conservation of bulky hydrophobic and aromatic substrate binding residues of the IDE active site, including 
several regions that are important for the formation of β-structures. In addition, several specificity 
determinants of the IDE active site are characterized here.    
First, IDE residues A140, F141 and Y150 collectively make up the proteolytic S1 subsite. Notably, these 
residues are contained on the β6 strand of IDE, which adopts β-structure interactions with various IDE 
substrates (24).  The S1 subsite partially envelops bound substrates in the P1 position directly amino terminal 
to the hydrolyzed peptide bond. Functional conservation of the S1 subsite is critical to substrate binding and 
proteolysis, as introduction hydrophilic or charged aliphatic residues in place of residues A140, F141 and Y150 
substantially attenuates IDE proteolytic activity and reduces binding affinity towards insulin B chain and Aβ 
peptide derivative FRET substrates. 
Second, the IDE S1’ subsite comprises residues F115, F820 and Y831.  These residues are positioned in 
proximity to hydrophobic P1’ residues of insulin B chain (L17) and Aβ 1-40 (F20). Residues of the IDE S1’ 
subsite form a contact interface with bound substrates directly adjacent to the position of a common β-turn 
(23, 24). Together with the requirement for hydrophobic or aromatic residues in the S1 subsite, the 
requirement for hydrophobic and/or aromatic residues in the S1’ position is consistent with a model in which 
IDE specificity is preferentially directed towards substrates bearing hydrophobic and aromatic amino acids 
directly adjacent to the scissile peptide bond (i.e., in the P1 and P1’ positions) (27).  
Third, an extended substrate binding site comprises at minimum residues W199 and F202 of the α5 helix 
of the IDE N-terminal subunit. Residue W199 is positioned within 4.5 Å of the P4, P3, and P2 substituents of 
insulin B chain (residues E13, A14, and L15) and Aβ 1-40 (residues K16, L17, and V18, respectively), and 
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together with residue F202 serves to cradle substrates in the P4 position near the boundary of defined 
substrate electron density in the crystal structures PDB ID 2G54 and PDB ID 2G47 (23). Conservation of the 
bulk, aromaticity and hydrophobicity of IDE residues W199 and F202 is critical to enzyme activity.   
The functional requirement for IDE active site residues investigated here represents an important 
component of the broader model for IDE function, which must additionally account for extended substrate 
binding and mechanistic contributions much further removed from the enzyme active site. A more 
comprehensive model must therefore consider extended and potentially networked interactions occurring 
within the IDE allosteric (31) and exosites (28,29), which are not directly characterized here. Moreover, while 
all mutants characterized in this study were expressed with comparable yield and readily purified as proteins 
of the expected molecular mass (Fig. S1), we cannot rule out the possibility that introduced mutations may 
bring about a profound modification of the IDE active site micro-architecture which influences substrate 
specificity and kinetics of peptide hydrolysis. 
Collectively, the findings from this study and others (23, 24, 25, 26, 27) support a model in which 
hydrophobic and aromatic residues of the IDE active site serve to limit or direct solvent accessibility during 
peptide hydrolysis by maintaining hydrophobic contacts, pi-stacking and β-structure interactions with bound 
substrates directly proximal to the scissile peptide bond.  We speculate that the IDE active site residues 
characterized here play critical roles in the IDE catalytic mechanism by increasing the thermodynamic 
favorability of productive enzyme-substrate interactions, and by positioning bound peptide substrates in the 
appropriate orientation for proteolysis. By defining the characteristics of the IDE active site that are required 
for enzymatic specificity and proteolysis, this study contributes functional data informing the mechanism of 
action of IDE and related M16 proteases. This information may serve to guide therapeutic strategies for 
controlling IDE function through development of IDE inhibitors or substrate analogs targeting critical 
interactions within the enzyme active site, presenting intriguing opportunities for future research. 
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MATERIALS AND METHODS 
Cloning, recombinant expression and purification of human IDE and derivative mutants 
Human IDE was obtained much as previously described for related enzymes of the M16A subfamily (36, 
37). The IDE gene characterized in this study was amplified from the GE Dharmacon™ cDNA library (product 
MHS6278-211689641 clone ID 40008464; GENBANK reference sequence BC096336) (38, 39). For bacterial 
expression, IDE was inserted from 5’ to 3’ at Nde1 and Xho1 cloning sites, respectively, in the pET-30b(+) 
expression vector (Novagen, Inc.) by gap cloning using the In-Fusion® HD cloning kit (Takara Bio Sciences).    
Plasmid constructs directed expression of a C-terminal polyhistidine fusion protein bearing an N-
terminal truncation relative to the BC096336 reference gene sequence (i.e., IDE(M42-L1019)-6xHis). Derivative 
mutations were introduced by circular PCR amplification of the WT IDE expression construct using mutagenic 
oligonucleotides (Table S1). The WT IDE plasmid expression construct was validated by DNA sequencing 
throughout the full open reading frame, while derivative clones were validated across the site of mutation or 
truncation only (Keck DNA sequencing facility, Yale University; data not shown). 
Bacterial cells (strain BL21 DE3) expressing WT IDE or derivative mutants were cultured in lysogeny 
broth supplemented with 50 μg/mL kanamycin antibiotic and induced for protein expression using 0.1 mM 
isopropyl β-D-1 thiogalactopyranoside (IPTG).  Following induction, cultured cells were grown overnight at 25 
°C, harvested by centrifugation, rinsed with phosphate buffered saline, and stored at -80 °C prior to cell lysis.  
Cell lysis was achieved by ultrasonic disruption, and cell lysates were clarified by centrifugation (3,200 g x 20 
minutes at 4 °C). Clarified cell lysates were purified by nickel affinity chromatography using a Ni2+-IDA resin in 
accordance with conditions recommended by the manufacturer (Takara Bio Sciences). Protein concentration 
was determined by Bradford assay prior to supplementation with glycerol and storage at -20 °C. 
 
Development and application of insulin B chain and Aβ peptide derivative FRET substrates for kinetic studies 
of IDE proteolytic activity 
Insulin B chain (Mca-VEALYLVCGEK(Dnp)-OH) and Aβ peptide derivative (Mca-QKLVFFAEDVK(Dnp)-OH) 
FRET substrates were developed as novel tools for the characterization of IDE proteolytic activity in vitro. FRET 
substrates were engineered to approximate the core regions of electron density for insulin B chain and Aβ 1-
40 peptides at the IDE active site based on the available crystal structures (23). By comparison with 
established physiological substrates, FRET substrates used in this study comprised 5 amino acid residues N- 
and C-terminal to primary reported sites of IDE mediated cleavage of insulin B chain and Aβ 1-40 (23, 35, 40) 
flanked by N-terminal Mca fluorescing groups and C-terminal fluorescence-quenching K(Dnp) moieties.  
Insulin B chain and Aβ peptide derivative quenched fluorogenic substrates (Mca-VEALYLVCGEK(Dnp)-OH 
and Mca-QKLVFFAEDVK(Dnp)-OH were synthesized using standard 9-fluorenylmoethyloxycarbonyl (Fmoc)- 
based chemistry with an Fmoc-Lys(Dnp) Wang resin on an automated peptide synthesizer (PS3, Gyros Protein 
Technologies, Inc.). The 7-methoxycoumarin-3-carboxylic acid was attached to each peptide backbone at the 
N-terminus using standard 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate 
(HBTU) coupling protocols. Peptides were cleaved from the resin using a cleavage cocktail of trifluoroacetic 
acid/ thioanisole/ethanedithiol/anisole (90/5/3/2) at room temperature for three hours. The peptides 
precipitated into ice-cold diethyl ether and were pelleted by centrifugation at 1300 x g for 10 minutes. The 
peptide pellets were then washed with diethylether and centrifuged two additional times.  
FRET substrates were purified by reverse-phase HPLC (Shimadzu Prominence) with a Phenomenex Aeris 
Peptide C-18 semi-preparative column (150 x 10 mm) using a 3 mL/minute flow rate and a linear gradient of 
60-80% and 45-65% acetonitrile over 15 minutes for Mca-VEALYLVGEK(Dnp)-OH and Mca-QKLVFFAEDK(Dnp)-
OH peptides, respectively. The peptide product mass was confirmed by MALDI-TOF on a Shimadzu Axima 
Confidence mass spectrometer using α-cyano-4-hydroxycinnamic acid (CHCA) as matrix (Figure S3 and S4). 
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FMOC Lys(Dnp) Wang resin was purchased from Anaspec, Inc., and 7-methoxycoumarin-3-carboxylic acid was 
purchased from Chemodex, Inc. The FMOC protected amino acids, HBTU, deprotection solution, activating 
reagent, TFA, DMF and DCM were purchased from Gyros Protein Technologies, Inc. All other reagents were 
purchased from Fisher Scientific, Inc. Synthesis and purification of FRET substrates were further confirmed by 
mass spectrometric analysis of the HPLC purified peptides (Fig S3, S4). 
 
Kinetic assays for IDE proteolysis of insulin and Aβ  peptide derivative FRET substrates 
To assess the role of IDE active site mutants in substrate binding and proteolysis, insulin B chain and Aβ 
peptide derivative FRET substrates were used to evaluate IDE activity in real time. For proteolysis assays to 
determine the specific activity of WT IDE and derivative mutants, a 50 µL reaction mixture was assembled 
containing 50 nM IDE and 20 µM of Mca-VEALYLVCGEK(Dnp)-OH or 25 nM IDE and 20 µM Mca-
QKLVFFAEDVK(Dnp)-OH in a reaction buffer of 50 mM Tris(hydroxymethy) aminomethane, pH 7.3. To limit 
potential peptide aggregation, substrates were bath sonicated for 5 minutes at room temperature prior to 
assembling the enzymatic reaction mixture. Enzyme and substrate pre-mixtures were prepared independently 
and warmed to 37 °C prior to sample mixing and initiation of the proteolytic assay.  
Fluorescence was measured using a Biotek Synergy HT plate reader (excitation: 325 ± 25 nm, emission: 
420 ± 25 nm). Quantitative standardization of Mca-VEALYLVCGEK(Dnp)-OH and Mca-QKLVFFAEDVK(Dnp)-OH 
hydrolysis was achieved by determining fluorescence yield relative to known concentrations of Substrate V 
(Mca-RPPGFSAFK(Dnp), with linearity of fluorescence yield as function of product concentration established 
through the preparation of serially diluted peptide standards. To evaluate the functional consequences of IDE 
mutation with respect to substrate specificity and binding affinity, kinetic assays were conducted while varying 
initial substrate concentrations from 1.25-20 µM. Kinetic parameters including substrate concentrations that 
corresponded with half-maximal enzymatic activity (Khalf; an approximation of binding affinity for allosteric 
enzymes) and maximal rate of substrate turnover (kcat) were determined by non-linear regression using the 
allosteric sigmoidal least squares regression function (Y = Vmax • X
h 
/ (Khalf
h 
+ X
h
), X = [S]) of the GraphPad PRISM 
7 graphical analysis software.  
 
FRET substrate proteolytic cleavage site mapping  
To map IDE proteolytic cleavage sites within the internally quenched fluorogenic insulin B chain and Aβ 
derivative FRET substrates Mca-VEALYLVCGEK(Dnp)-OH and Mca-QKLVFFAEDVK(Dnp)-OH, 50 µL of a 
quenching solution containing 500 mM EDTA and 2% TFA were added to the 50 µL enzymatic assay mixtures 
at the midpoint of the proteolysis experiment. Samples were stored at -80 °C prior to analysis of peptide 
cleavage sites by MALDI-TOF mass spectrometry.  A 25 µL aliquot of the quenched reaction mixture was 
prepared for MALDI-TOF mass spectrometry analysis with a C18 Reverse-Phase ZipTip® (Millipore) following 
manufacturer protocols. MALDI-TOF mass spectrometry analysis of FRET substrate IDE cleavage sites was 
mapped using CHCA MALDI matrix in reflectron mode and post-source decay MS/MS was conducted on major 
cleavage site peptide fragments (Axima Confidence, Shimadzu). 
Mass spectrometric analysis of IDE proteolyzed Mca-VEALYLVCGEK(Dnp)-OH indicated a major cleavage 
site between the central tyrosine and leucine residues Y5 and L6 of the hendecameric peptide (Fig S5A and 
S5B). This site of hydrolysis is analogous to a major reported IDE cleavage site within insulin B chain, which is 
cleaved by IDE at the Y16 -L17 peptide bond and elsewhere (23, 41, 42). C-terminal post-source decay 
sequencing of this major peptide fragment confirmed the hydrolysis product as Mca-VEALY-OH (Figure S5C 
AND S5D). Mass spectrometric analysis of IDE proteolyzed Mca-QKLVFFAEDK(Dnp)-OH indicated a primary 
peptide cleavage site between the two central phenylalanine residues F5 and F6 (Figure S6A and S6B).  This 
site of hydrolysis is analogous to a major reported IDE cleavage site within Aβ 1-40, which is cleaved by IDE at 
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the central F19-F20 peptide bond, as well as at other sites within the polypeptide (16, 23, 40, 43, 44).  C-
terminal post-source decay sequencing of the major peptide fragment confirmed the hydrolysis product as 
Mca-QKLVF-OH (Figure S6C and S6D).  
  
Insulin and Aβ 1-40 proteolysis assays 
To assess the impact of IDE active site mutations on proteolysis of intact insulin and Aβ 1-40, kinetic 
assays were conducted using purified recombinant peptides. IDE proteolysis assays were performed using 
labeled insulin (fluorescein isothiocyanate labeled recombinant human insulin peptide expressed in yeast, 
Sigma Aldrich Inc.) and unlabeled Aβ 1-40 peptides (HFIP-pretreated human recombinant peptide expressed in 
E. coli, rPeptide Inc.) and were evaluated by SDS-PAGE.  
For insulin-FITC proteolysis experiments, enzymatic reactions contained 1.6 µg (180 nM) purified IDE 
and 400 ng (0.78 µM) insulin-FITC within an 80 µl reaction mixture buffered with 50 mM Tris, pH 7.3. For Aβ 1-
40 proteolysis experiments, enzymatic reactions contained 4 µg (0.45 µM) IDE and 16 µg (45 µM) Aβ 1-40 
within an 80 µl reaction mixture buffered with 50 mM Tris, pH 7.3. Enzyme and substrate pre-mixtures were 
initially prepared at 2X working concentration, and peptides were bath sonicated in reaction buffer prior to 
sample mixing to limit potential aggregation during the assay. Enzyme and substrate pre-mixtures were 
warmed before mixing. Proteolysis assays were conducted at 37 °C.  
To terminate the proteolytic reaction, 5 µl aliquots were drawn from the assay mixtures at the time 
points indicated and transferred to 10 µl of an SDS-PAGE sample loading buffer/stop solution of 100 mM 
EDTA, 160 mM Tris, pH 6.8, 0.32% bromophenol blue, 32% glycerol and 160 mM β-mercaptoethanol. Thus 
inactivated, samples were held on ice for the remainder of the proteolytic experiment, then heated to 95 °C 
for 3 minutes directly prior to SDS-PAGE sample loading and analysis. An amount of the enzymatic reaction 
mixture equivalent to an initial substrate load of either 25 ng insulin-FITC or 1 μg Aβ 1-40 (i.e., for each time 
point, the entire proteolytic sample) was then input to individual wells of a Bio-Rad Any kDaTM TGX 
polyacrylamide gel and separated under denaturing conditions in the presence of a Tris-glycine SDS page 
running buffer.  To limit background fluorescence, SDS-PAGE gels for insulin-FITC proteolysis experiments 
were pre-run at 150 V x 20 minutes prior to sample loading and electrophoretic separation. 
Following electrophoresis (150 V x 45 min), SDS-PAGE gels for the insulin-FITC proteolysis assay were 
rinsed briefly with water (1-5 s), and immediately subjected to UV transillumination fluorescence imaging.  
SDS-PAGE gels for the Aβ 1-40 proteolytic assay were stained overnight using colloidal Coomassie Brilliant 
BlueTM G250 (45) and then destained for approximately 4 h prior to photographic scanning with white light 
transillumination. Quantitative densitometric analysis was performed using Bio-Rad Image LabTM version 6.0 
software. In each gel, internal standards from serial dilution of insulin-FITC or Aβ 1-40 were used to determine 
the amount of peptide remaining throughout the proteolytic assay. 
 
 
ASSOCIATED CONTENT 
Supporting information. Purification of IDE mutants, primary sequence conservation of IDE homologs, 
validation of synthesis and fluorogenic substrate cleavage site mapping, a comparison of kinetic models for 
IDE function, SDS-PAGE and densitometric data for insulin-FITC and Aβ 1-40 proteolysis assays, 
oligonucleotides for construction of IDE mutants, substrate interfacing IDE residues targeted for mutagenesis, 
and properties of free amino acids used for mutagenic substitution analysis are presented in the supporting 
information. 
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